Literature DB >> 7646821

Hirudin and excess bleeding. Implications for future use.

U Zeymer1, K L Neuhaus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7646821     DOI： 10.2165/00002018-199512040-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  27 in total

1.  Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.

Authors:  T Yasuda; H K Gold; H Yaoita; R C Leinbach; J L Guerrero; I K Jang; R Holt; J T Fallon; D Collen
Journal:  J Am Coll Cardiol       Date:  1990-09       Impact factor: 24.094

Review 2.  The development of hirudin as an antithrombotic drug.

Authors:  F Markwardt
Journal:  Thromb Res       Date:  1994-04-01       Impact factor: 3.944

3.  Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.

Authors:  M Mirshahi; J Soria; C Soria; R Faivre; H Lu; M Courtney; C Roitsch; D Tripier; J P Caen
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

4.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

Review 5.  Direct thrombin inhibitors in cardiovascular medicine.

Authors:  J Lefkovits; E J Topol
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

6.  Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis.

Authors:  R P Harvey; E Degryse; L Stefani; F Schamber; J P Cazenave; M Courtney; P Tolstoshev; J P Lecocq
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

7.  Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies.

Authors:  A Vogt; R von Essen; U Tebbe; W Feuerer; K F Appel; K L Neuhaus
Journal:  J Am Coll Cardiol       Date:  1993-05       Impact factor: 24.094

8.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.

Authors: 
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

9.  Frequency of achieving optimal reperfusion with thrombolysis in acute myocardial infarction (analysis of four German multicenter studies).

Authors:  A Vogt; R von Essen; U Tebbe; W Feuerer; K F Appel; W Niederer; K L Neuhaus
Journal:  Am J Cardiol       Date:  1994-07-01       Impact factor: 2.778

Review 10.  Hirudins: antithrombin anticoagulants.

Authors:  K A Stringer; J Lindenfeld
Journal:  Ann Pharmacother       Date:  1992-12       Impact factor: 3.154
View more
  2 in total

1.  A phase I, single and continuous dose administration study on the safety, tolerability, and pharmacokinetics of neorudin, a novel recombinant anticoagulant protein, in healthy subjects.

Authors:  Yubin Liu; Meixia Wang; Xiaona Dong; Jia He; Lin Zhang; Ying Zhou; Xia Xia; Guifang Dou; Chu-Tse Wu; Jide Jin
Journal:  Pharmacol Res Perspect       Date:  2021-05

2.  Inhibitory role of recombinant neorudin on canine coronary artery thrombosis.

Authors:  Yu-Bin Liu; Xing-Chen Zhou; Yun Liu; Lin Zhang; Ying Zhou; Xiao Xu; Can Zheng; Zhuan-You Zhao; Chu-Tse Wu; Ji-de Jin
Journal:  Pharmacol Res Perspect       Date:  2022-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.